


## Curriculum Vitae

\* Within 3 pages

	<b>Name in Full</b>	Hana Alguel
	<b>Country</b>	Germany
	<b>Affiliation</b>	Comprehensive Cancer Center Munich, Klinikum rechts der Isar, Technical University of Munich
	<b>Email</b>	hana.alguel@mri.tum.de

<b>Educational Background</b>		
<b>Institution name</b>	<b>Qualification</b>	<b>Year</b>
II. Medical Department, Klinikum rechts der Isar, TUM	Gastroenterology	10/2011
II. Medical Department, Klinikum rechts der Isar, TUM	Gastrointestinal Oncology (AGIO)	04/2009
Bayerische Landesärztekammer	Board Certificate "Internal Medicine"	10/2008
II. Medical Department, Klinikum rechts der Isar, TUM	Principal Investigator of the scientific group "inflammation and cancer in the pancreas"	2007
Stuttgart	Accreditation	01/2002

<b>Professional Career</b>			
<b>Position</b>	<b>Institution name and Department</b>	<b>Start Year</b>	<b>End Year</b>
Director	Comprehensive Cancer Center Munich Technical University of Munich (TUM)	05/19	ongoing
Director	Institute for Tumor Metabolism	03/17	ongoing
Head of the Infectious Disease Unit	II. Medical Department, Klinikum rechts der Isar, TUM	05/2013	05/19
Head of the Gastro- intestinal Oncology Unit	II. Medical Department, Klinikum rechts der Isar, TUM	02/2013	ongoing

Senior Consultant	II. Medical Department, Klinikum rechts der Isar, TUM	05/2009	05/19
Resident	II. Medical Department, Klinikum rechts der Isar, TUM	01/2003	04/2009
Resident	Internal Medicine I, University of Ulm	06/2000	12/2002

## Research Field

Translational Oncology

Inflammation associated Carcinogenesis in the Pancreas

Targeted Therapy in Pancreatic Cancer

Acute and Chronic Inflammation in the Pancreas

1. Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. *Ann Oncol* 2023;34:91-100.
2. Wang X, Istvanffy R, Ye L, Teller S, Laschinger M, Diakopoulos KN, et al. Phenotype screens of murine pancreatic cancer identify a Tgfa-Ccl2-paxillin axis driving human-like neural invasion. *J Clin Invest* 2023.
3. Alonso-Nocelo M, Ruiz-Canas L, Sancho P, Gorgulu K, Alcalá S, Pedrero C, et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. *Gut* 2023;72:345-59.
4. Frank KJ, Mulero-Sanchez A, Berninger A, Ruiz-Canas L, Bosma A, Gorgulu K, et al. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. *Cell Rep Med* 2022;3:100815.
5. Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *J Clin Oncol* 2022;40:3929-39.
6. Ai J, Wormann SM, Gorgulu K, Vallespinos M, Zagorac S, Alcalá S, et al. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. *Gastroenterology* 2021;161:318-32 e9.
7. Kabacaoglu D, Ruess DA, Gorgulu K, Steiger K, Lesina M, Algul H. A Pancreas-Specific Ptf1a-Driven Cre Mouse Line Causes Paternally Transmitted Germline Recombination. *Gastroenterology* 2021;161:1695-7 e4.
8. Gorgulu K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, et al. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. *Gastroenterology* 2019;156:203-17 e20.
9. Ruess DA, Heynen GJ, Ciecieski KJ, Ai J, Berninger A, Kabacaoglu D, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. *Nat Med* 2018;24:954-60.

10. Lesina M, Wormann SM, Morton J, Diakopoulos KN, Korneeva O, Wimmer M, et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. *J Clin Invest* 2016;126:2919-32.

